title: [The effects of short-term high-dose statins on the prevention of contrast-induced nephropathy in patients undertaking coronary angiography: a systematic review and meta-analysis].
abstract: OBJECTIVE
  To assess the effects of short-term (2 - 7 d) high-dose (80 mg/d) statins in the prevention of contrast-induced nephropathy (CIN).
  
  
  METHODS
  We searched PubMed, Embase, Science Direct, Scopus, Ovid and Wiley Inter Science with the key words of "statins/statin/HMG-CoA reductase inhibitor", "contrast" and "nephropathy/nephrosis/nephrotoxicity/kidney failure" in all languages from 1996 to 2010 for RCT that assessed the preventive effect of short-term (2 - 7 d) high-dose (80 mg/d) statins on CIN.
  
  
  RESULTS
  Five trials with a total of 1009 patients were identified. Two studies were conducted in patients with CKD 3-5 stages (GFR ≤ 60 ml/min or serum creatinine ≥ 97.2 µmol/L) and the remaining 3 studies were conducted in patients with CKD 1 and 2 stages. Analysis of the data in patients with CKD 3-5 stages did not reveal a statistically significant difference in CIN incidence between the statins and placebo groups (6.5% vs 7.2%). The relative risk (RR) was 0.89 without evidence of heterogeneity (I(2) = 0%, P = 0.79). Analysis of the data in patients with CKD 1 and 2 stages revealed a significantly lower CIN incidence in the statins group (3.6%) than that in the placebo group (11.9%). The RR was 0.28 without evidence of heterogeneity (I(2) = 0%, P = 0.87).
  
  
  CONCLUSIONS
  Short-term high-dose statins treatment may be beneficial in reducing the incidence of CIN in patients with CKD 1 and 2 stages, while no benefit has been shown in the patients with CKD 3-5 stages.
authors.affiliation: Department of Nephrology, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Wei-jie
authors.initials: WJ
authors.lastname: Yuan
mesh_terms: D058186:Acute Kidney Injury; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D003287:Contrast Media; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors